文献速递血栓与止血

预测静脉血栓栓塞症抗凝3个月后临床显著出血的新型动态风险评分

A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer.
PubMed 文献 · J Thromb Haemost · 2026-06-18

本研究基于英国临床实践研究数据链(2001-2020)构建回顾性队列,纳入首次静脉血栓栓塞症且已完成3个月抗凝治疗的患者,开发了一种动态、宽泛、治疗调整的临床显著出血(CSB)风险评分。在51 621例患者、206 298人年的观察中,共识别3 301例CSB事件,10年CSB发病率为1.60/100人年。模型纳入18个独立预测因子,评分0至≥14分,区分度稳定(C统计量0.78,95%CI 0.77-0.79),可动态预测出血风险并考虑抗凝状态。

要点

  • 该动态评分可识别抗凝3个月后CSB高风险患者,C统计量0.78。
  • 模型含18个独立预测因子,评分0至≥14分,风险随分值升高。
  • 第一年CSB风险从0.60%(0分)至18.1%(≥14分)。

核心结论

  • 动态评分能有效识别抗凝3个月后临床显著出血风险,区分度优秀。
  • 该评分可随时间动态预测出血风险,并考虑抗凝状态。

研究设计与样本

  • 基于英国临床实践研究数据链(2001-2020)的回顾性队列。
  • 纳入51 621例首次静脉血栓栓塞症且已完成3个月抗凝治疗的患者。
  • 采用Fine-Gray模型估计风险比,并构建 additive(对数)评分方案。

主要发现

  • 共识别3 301例CSB事件,观察206 298人年,10年CSB发病率为1.60/100人年。
  • 模型纳入18个独立预测因子,评分范围0至≥14分。
  • 10年内CSB风险逐年下降,但每年内风险随评分类别升高,第一年从0.60%至18.1%。
  • 校准斜率:基础模型0.81(0.76-0.87),扩展模型0.95(0.88-1.02),绝对截距均<0.001。
  • 区分度稳定,C统计量为0.78(0.77-0.79)。

关键数值与推荐

  • CSB 10年发病率为1.60/100人年。
  • 第一年CSB风险范围0.60%(0分)至18.1%(≥14分)。
  • C统计量0.78(95%CI 0.77-0.79)。

临床怎么用

  • 可用于抗凝3个月后动态评估临床显著出血风险,辅助决定是否长期抗凝。
  • 评分考虑抗凝状态随时间变化,支持动态风险预测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: After 3 months of treatment, clinicians and patients need to decide whether to continue anticoagulant therapy long-term, which is informed by bleeding risk; to date, we have not had a reliable way to estimate that risk. OBJECTIVES: To develop a dynamic, broad, treatment-adjusted risk score for clinically significant bleeding (CSB). METHODS: UK Clinical Practice Research Datalink (2001-2020) was used to generate a retrospective cohort of patients with their first venous thromboembolism who had received 3 months of anticoagulation. Covariates were collected at baseline and as time-varying data. Hazards with 95% CIs were estimated using a Fine-Gray model. A dynamic model with an additive (logarithmic) scoring scheme was developed from sub-distribution hazard ratios. Discrimination was expressed by the C-statistic. RESULTS: In 51 621 patients with venous thromboembolism, 3301 CSB events were identified in 206 298 person-years of observation. The 10-year incidence rate for CSB was 1.60 per 100 person-years. The model incorporated 18 independent predictors of CSB, assigning risk scores from 0 to ≥14. The risk of CSB decreased over 10 years, but within each year, it increased by point category, ranging from 0.60% to 18.1% in the first year (0-≥14 points). Calibration slopes were 0.81 (0.76-0.87) base model and 0.95 (0.88-1.02) extended model; absolute intercepts were <0.001 in both. Discrimination was stable, with a C-statistic of 0.78 (0.77-0.79). CONCLUSION: Our dynamic score effectively identifies patients at risk of CSB, following 3 months of anticoagulant therapy, with excellent discrimination. It enables dynamic prediction of bleeding risk over time, accounting for anticoagulation status.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Choudhuri S, Cohen AT, Khan I, et al. A novel dynamic risk score to predict clinically significant bleeding after 3 months of anticoagulation in patients with incident venous thromboembolism and without active cancer. J Thromb Haemost. 2026. PMID: 42315025. doi:10.1016/j.jtha.2026.06.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。